Skip to content

High-intensity Interval Training on Cardiorespiratory Fitness in Overweight Women

Effect of Low-volume High-intensity Interval Training on Cardiorespiratory Fitness and Total Body Fat in Overweight Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03300895
Enrollment
35
Registered
2017-10-04
Start date
2017-08-14
Completion date
2018-11-30
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

High-intensity interval training (HIIT) is currently considered one of the most effective strategies to improved cardiorespiratory fitness, which is recognized as a protective factor for cardiovascular diseases and metabolic diseases such as overweight and obesity. However, current evidence is still limited and requires clarity (frequency, time per session and intensity) regarding to greater increases attributed to HIIT. The aim of this study is to compare the effect of a low-volume high-intensity interval training versus a moderate-intensity continuous exercise on maximal oxygen consumption in overweight women 18 to 44 years old.

Detailed description

Thirty-six women will be randomly assigned to one of two aerobic exercise on a real-life setting supervised for a physical activity instructor. The interventions will performed three times a week for ten-weeks (on alternate days). The first two weeks will correspond to the conditioning period (30 minutes between 55-65% of maximum heart rate (HRmax). From week three, 18 participants will perform 30 minutes of continuous exercise at an intensity between 65-75 % of HRmax, and the remaining 18 will complete 21.5 minutes of interval exercise at an intensity between 90-95% of HRmax, with recoveries between 50-55% of HRmax. All Participants will be evaluated to measure their maximal oxygen consumption, total body fat, waist circumference, body mass index, systolic blood pressure, diastolic blood pressure, prior to start the interventions and at the end of the program (week 11).

Interventions

OTHERHigh-intensity interval training

21.5 minutes of high-intensity interval exercise at an intensity between 90-95 of HRmax (15x30 s), with recoveries at 50-60% of HRmax (14x60 s). 24 sessions, 3x weekly of walking and running outdoors on a sports field in a supervised manner.

OTHERComparator: Moderate-intensity continuous exercise

30 minutes of continuous exercise at an intensity between 65-75% of HRmax. 24 sessions, 3x weekly of walking and jogging outdoors on a sports field in a supervised manner

Sponsors

Universidad de Antioquia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 44 Years
Healthy volunteers
Yes

Inclusion criteria

* Overweight (≥ 25 kg/m-2) women 18 to 44 years. * Healthy volunteers. * Perform ≤ 600 Met/min/week.

Exclusion criteria

* Perform high-intensity interval exercise in the last six month. * Smoker. * History of asthma. * History of diabetes. * History of hypertension. * History of cardiovascular disease. * History of coronary heart disease. * Arrhythmias. * Personal history of surgical procedures in the last three months * Uncontrolled non-communicable diseases * Under medical treatment with anticoagulants, beta-blockers, calcium antagonists, bronchodilators, and/or steroids. * Psychological, neuromotor and/or osteo-muscular conditions that may affect participation in an exercise program. * Psychoactive drug abuse.

Design outcomes

Primary

MeasureTime frameDescription
Change in maximal oxygen consumptionBaseline and after 10 weeksMaximal oxygen consumption will be obtained using a graded exercise test on a treadmill (Trackmaster® model TMX 425C) using a portable K4b2 gas analyzer (Cosmed Inc., IL, USA)

Secondary

MeasureTime frameDescription
Change in total body fatBaseline and after 10 weeksTotal body fat will be obtained using an Omron® HBF-510 (Omron Healthcare, Inc. Bannockburn, IL, USA) bioelectrical impedance machine.

Countries

Colombia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026